The short version of nootropic fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2025-07-26 and is reviewed periodically as new material appears.
Regulatory status varies sharply by country. Semax is registered for medical use in Russia, where it appears in formularies as a nasal solution, and it also holds registration in a small number of neighbouring states. It has no approval from the United States Food and Drug Administration or the European Medicines Agency, and it is not a scheduled controlled substance in most jurisdictions. Elsewhere it circulates mainly as laboratory material, so purity documentation comes from suppliers rather than from a national pharmacopoeia.
Semax is a synthetic peptide created in the Soviet Union during the early 1980s by researchers working in Moscow. It was built from the short adrenocorticotropic hormone fragment known as ACTH(4-10), and the chain was then extended with three additional amino acids. The resulting molecule was named semax and entered clinical use in Russia in 1994. It is generally described as a nootropic and neuroprotective agent rather than as a hormone analogue.
Published research on this peptide originates mainly from Russian laboratories, and the wider international literature is comparatively thin. Studies have used rodent models of stroke, hypoxia, and memory tasks, with a smaller number of human trials reported. Reported outcomes include changes in attention and memory measures, along with effects on neurotrophic factor expression in some experiments. Small sample sizes, inconsistent dosing protocols, and limited independent replication are widely noted limitations, so the strength of the clinical evidence remains an open question.
Semax is a synthetic heptapeptide whose sequence is Met-Glu-His-Phe-Pro-Gly-Pro. The first four residues correspond to the ACTH(4-10) fragment, while the terminal Pro-Gly-Pro extension was added to improve metabolic stability. Its molecular formula is C37H51N9O10S and its monoisotopic mass is approximately 813.9 Da. The compound is classified as a peptide research chemical and as a registered pharmaceutical product in Russia, but it does not hold marketing approval in the European Union or the United States. Naming conventions vary across supplier catalogs.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic heptapeptide | Analogue of the ACTH(4-10) fragment |
| Amino acid sequence | Met-Glu-His-Phe-Pro-Gly-Pro | Single-letter form MEHFPGP |
| Molecular formula | C37H51N9O10S | Free peptide, nominal mass near 814 Da |
| First registration | 1994, Russia | Nasal formulation for neurological indications |
| Typical purity grade | 95% or higher by HPLC | Research material; higher grades used as reference standards |
该化合物于二十世纪八十年代在俄罗斯被开发，相关工作由俄罗斯科学院分子遗传学研究所的研究团队主导。开发目标并非复制 ACTH 的完整激素活性，而是寻找保留其神经作用方向、同时去除促肾上腺皮质激素释放效应的短肽片段。研究记录显示，这一方向促成了多个相关短肽的合成与筛选，而 Semax 是其中被研究最广泛的一个。当地文献常以 Семакс 这一名称指代它。
研究兴趣主要集中在神经营养因子相关的路径上，包括脑源性神经营养因子与神经生长因子的表达变化。部分实验报告称在特定条件下观察到这些因子的水平上升，但具体信号通路和剂量依赖关系仍未完全厘清。多数公开数据来自细胞模型和动物实验，人体对照研究数量有限。因此，该化合物的作用机制在文献中属于活跃讨论，而非已经确立的定论。
Semax 是一种人工合成的七肽，氨基酸序列为 Met-Glu-His-Phe-Pro-Gly-Pro，单字母缩写记作 MEHFPGP。它被归类为促肾上腺皮质激素片段 ACTH(4-10) 的结构类似物，但并不天然存在于生物体内。母体片段 ACTH(4-10) 的序列为 Met-Glu-His-Phe-Arg-Trp-Gly，Semax 替换了中间两个残基，并在羧基端延长了 Pro-Gly-Pro 三肽。这种延长被普遍认为能提升分子对肽酶的耐受性。
Semax is a synthetic heptapeptide whose sequence is Met-Glu-His-Phe-Pro-Gly-Pro. It was developed as a fragment analog of adrenocorticotropic hormone, modeled specifically on the ACTH(4-10) region. The first four residues reproduce that fragment, while a Pro-Gly-Pro tripeptide is appended at the C-terminus. Work on the compound originated in Russia, where it entered clinical use as an intranasal preparation. Its sequence places it among short regulatory peptides studied for effects on the central nervous system rather than on the adrenal axis.
The C-terminal Pro-Gly-Pro extension is not incidental. Proline-rich tails are known to resist several common peptidases, and the published literature attributes the longer half-life of Semax, relative to unmodified ACTH fragments, to this feature. The modification also removes the melanocyte-stimulating and corticosteroidogenic activity that characterizes longer ACTH-derived sequences. Because the molecule is small and hydrophilic, it is typically formulated as an aqueous solution for intranasal or parenteral delivery. Acetylation or amidation at the termini appears in closely related research peptides and shifts the mass by a fixed increment.
Laboratory descriptions of the material are consistent across suppliers. It appears as a white to off-white lyophilized powder that dissolves readily in water and in polar organic solvents such as dimethyl sulfoxide. Aqueous solutions are clear and colorless at low concentrations. Because the peptide contains methionine, oxidation at the sulfur atom is a recognized degradation pathway, and handling notes usually call for protected, desiccated storage. Reported purity for research-grade lots is generally above 95 percent as measured by reversed-phase high-performance liquid chromatography.
The compound is registered in Russia as a pharmaceutical product, most commonly formulated as a nasal solution, and has been used in that setting since the 1990s. Outside that jurisdiction it is generally handled as a research chemical rather than an approved medicine. Regulatory status therefore differs sharply between countries, and material sold internationally may not correspond to the Russian pharmaceutical formulation. Documentation with commercial samples is typically limited to a certificate of analysis covering purity and identity, not clinical status or local legal classification.
Semax is a synthetic heptapeptide with the sequence Met-Glu-His-Phe-Pro-Gly-Pro. It corresponds to the ACTH(4-7) fragment extended at the C-terminus by a Pro-Gly-Pro tripeptide, an addition intended to slow enzymatic breakdown. The molecular formula is C37H51N9O10S and the molecular mass is approximately 814 daltons. In the literature it is often described as an ACTH(4-10) analog, although that label reflects a naming convention as much as a precise structural relationship. The compound was developed in Russia and remains most closely associated with that research tradition.
The compound was developed in the 1980s at the Institute of Molecular Genetics in Moscow, where it emerged from research on short ACTH fragments and their effects on the central nervous system. Russian pharmaceutical listings describe it as a nootropic and neuroprotective agent, most often formulated as nasal drops. It is not a marketed medicine in the United States or the European Union, and no pharmacopoeial monograph covers it. Consequently, most published clinical experience with the substance originates from a small number of research centres, mainly in Russia and neighbouring countries.
Pharmacological accounts link semax to melanocortin signalling and to modulation of neurotrophic factor expression, particularly brain-derived neurotrophic factor and nerve growth factor. Much of this evidence comes from rodent studies using intranasal delivery, a route chosen because it allows peptides to reach the central nervous system with limited systemic exposure. Whether the same mechanisms operate in humans at comparable magnitude remains an open question. The precise receptor or receptors responsible for the reported behavioural and neuroprotective effects have not been conclusively identified.
Clinical reports describe use in ischaemic stroke, transient ischaemic attack, optic nerve conditions, and cognitive complaints, but most of these studies are small and were conducted in a single region. Systematic reviews have generally described the evidence base as limited in size and variable in methodological quality. Randomised controlled data suitable for international regulatory assessment are scarce. As a result, major treatment guidelines outside Russia do not include the peptide, and interest in it remains largely research-driven rather than routine clinical.
== Adverse effects == Aminoglycosides can cause inner ear toxicity which can result in sensorineural hearing loss. The incidence of inner ear toxicity varies from 7 to 90%, depending on the types of antibiotics used, susceptibility of the patient to such antibiotics, and the duration of antibiotic administration. Another serious and disabling side effect of aminoglycoside use is vestibular ototoxicity. This leads to oscillopsia (gaze instability) and balance impairments that impact all aspects of an individual's antigravity function. This loss is permanent and can happen at any dose. Frequent use of aminoglycosides could result in kidney damage (acute kidney injury) that could lead to chronic kidney disease.
Breast milk supply increases in response to the baby's demand for milk and decreases when milk is allowed to remain in the breasts. When considering a possibly low milk supply, it is important to consider the difference between "perceived low milk supply" and "true low milk supply". Perceived low milk supply occurs when mothers, for a variety of reasons, believe that they are not making enough milk to feed their infant. These reasons may include fussiness, colic, preference for the bottle as opposed to the breast, long nursing duration, decreased sensation of breast fullness, and even decreased frequency of infant stools. However, in these cases, it is important to reassure the parent that infant weight gain is absolute proof of adequate milk intake. Thus, if the infant is breastfeeding exclusively and is gaining weight appropriately, then the parent can be reassured that they are producing enough milk. True low milk supply can be either primary (caused by medical conditions or anatomical issues in the mother), secondary (caused by not thoroughly and regularly removing milk from the breasts), or both. Primary causes may manifest before or during pregnancy, during labor, and even after birth. Secondary causes are far more common than primary ones. One study found that 15% of healthy first-time mothers had low milk supply 2–3 weeks after birth, with secondary causes accounting for at least two-thirds of those cases. Poor milk intake is signaled by poor infant weight gain, signs of dehydration, and hypoglycemia.
== Playing career == Because the population of Duttlenheim was short in numbers, it proved difficult to field a team of 11 players of equal ages; Wenger did not play for FC Duttlenheim until the age of 12. Claude Wenger, a teammate of Arsène's, noted his lack of pace as a player, which he made up for with his "ability to guard the ball, [seeming] to have a complete vision of the pitch and having an influence among his team-mates", according to Marcel Brandner, the president of FC Duttlenheim. As a young teenager, he was called Petit; the nickname ceased when he had a growth spurt and broke into FC Duttlenheim's first team, aged 16. The team did not have a coach to prepare the players tactically, rather a person who supervised training sessions. Wenger took it upon himself to manage the side, with Claude stating "Arsène wasn't the captain and yet he was. It was 'You do this, you do that, you do this, you do that.' He was the leader".
Gate of Flesh (Japanese: 肉體の門, Hepburn: Nikutai no mon) is a 1964 Japanese film based on a novel by Taijiro Tamura and directed by Seijun Suzuki. The first of Suzuki's "flesh trilogy" (followed by Story of a Prostitute and Carmen from Kawachi), the series is considered the "crowning achievement" of his period working at the production house Nikkatsu. The film is viewed as a direct and allegorical critique of Japan's Occupation and subsequent development, which rather than breaking with the country's pre-war militaristic, authoritarian social structures only sees their reconstitution in the post-war period.
== Target == Phrixotoxin-1 and -2 bind to A-type, transient, voltage-gated potassium channels, near the S3 and S4 segments, where they negatively affect transmembrane movement of the voltage sensing domain in response to depolarizing voltages. They bind preferentially to the closed or inactivated state of Kv4.2 and Kv4.3 channels(Chagot 2004). Phrixotoxin-3 (PaurTx3) inhibits several voltage gated sodium channel subtypes (Nav1.1/SCN1A, Nav1.2/SCN2A, Nav1.4/SCN4A, Nav1.5/SCN5A, and Nav1.8/SCN10A) (Bosmans 2006).
Sources: en.wikipedia.org
Even the territorial integrity of the country was in danger: On 7 March 1849, an imperial proclamation was issued in the name of the Emperor Francis Joseph, according to the new proclamation, the territory of Kingdom of Hungary would be carved up and administered by five military districts, while the Principality of Transylvania would be reestablished. These events represented a clear and obvious existential threat for the Hungarian state. The stadion constitution abolished Hungary’s separate constitutional statehood and reduced the Hungarian state to the status of a typical Habsburg province/crownland within a centralized Austrian Empire. The new constrained Stadion Constitution of Austria, the revocation of the April laws and the Austrian military campaign against the Kingdom of Hungary resulted in the fall of the pacifist Batthyány government (which sought agreement with the court) and led to the sudden emergence of Lajos Kossuth's followers in the Hungarian parliament, who demanded the full independence of Hungary. The Austrian military intervention in the Kingdom of Hungary resulted in strong anti-Habsburg sentiment among Hungarians, thus the events in Hungary grew into a war for total independence from the Habsburg dynasty.
==== MeSH D12.776.964.970.880 – viral envelope proteins ==== MeSH D12.776.964.970.880.325 – gene products, env MeSH D12.776.964.970.880.325.330 – hiv envelope protein gp41 MeSH D12.776.964.970.880.325.350 – hiv envelope protein gp120 MeSH D12.776.964.970.880.325.380 – hiv envelope protein gp160 MeSH D12.776.964.970.880.345 – hemagglutinins, viral MeSH D12.776.964.970.880.345.500 – hemagglutinin glycoproteins, influenza virus MeSH D12.776.964.970.880.350 – hn protein MeSH D12.776.964.970.880.910 – viral fusion proteins MeSH D12.776.964.970.880.910.330 – hiv envelope protein gp41 MeSH D12.776.964.970.880.940 – viral matrix proteins MeSH D12.776.964.970.880.940.580 – gene products, vpu
== History == Fentanyl was first synthesized in Belgium by Paul Janssen under the label of his relatively newly formed Janssen Pharmaceutica in 1959. It was developed by screening chemicals similar to pethidine (Demerol) for opioid activity. The widespread use of fentanyl triggered the production of fentanyl citrate (the salt formed by combining fentanyl and citric acid in a 1:1 stoichiometric ratio). Fentanyl citrate entered medical use as a general anesthetic in 1968, manufactured by McNeil Laboratories under the brand name Sublimaze. In the mid-1990s, Janssen Pharmaceutica developed and introduced into clinical trials the Duragesic patch, which is a formulation of an inert alcohol gel infused with select fentanyl doses, which are worn to provide constant administration of the opioid over 48 to 72 hours. After a set of successful clinical trials, Duragesic fentanyl patches were introduced into medical practice.
O-GlcNAc has been found to slow protein aggregation, though the generality of this phenomenon is unknown. Solid-phase peptide synthesis was used to prepare full-length α-synuclein with an O-GlcNAc modification at T72. Thioflavin T aggregation assays and transmission electron microscopy demonstrated that this modified α-synuclein does not readily form aggregates. Treatment of JNPL3 tau transgenic mice with an OGA inhibitor was shown to increase microtubule-associated protein tau O-GlcNAcylation. Immunohistochemistry analysis of the brainstem revealed decreased formation of neurofibrillary tangles. Recombinant O-GlcNAcylated tau was shown to aggregate slower than unmodified tau in an in vitro thioflavin S aggregation assay. Similar results were obtained for a recombinantly prepared O-GlcNAcylated TAB1 construct versus its unmodified form.
Sources: en.wikipedia.org
Registered medical products are most often 0.1% nasal drops. Research suppliers ship lyophilized powder, usually in milligram quantities, which is dissolved before use. The active peptide is the same in both cases; presentation and excipients differ.
No. The peptide is synthetic, although it is modelled on a fragment of a naturally occurring hormone. ACTH(4-10) is generated when ACTH is cleaved, but the Pro-Gly-Pro extension is not a known endogenous sequence. It is therefore a designed analogue rather than a natural metabolite.
The label reflects reported effects on attention, memory and recovery after neurological injury in regional clinical reports. Those reports are mostly small and have not been widely replicated outside the region. The classification is descriptive and does not imply a single defined mechanism.
It is a synthetic peptide of seven amino acids. Its backbone corresponds to a fragment of adrenocorticotropic hormone extended at the carboxyl end. The material is distributed as a lyophilized solid for laboratory use.